Be Swasth Healthcare Annual Reports, Balance Sheet and Financials

Be Swasth Healthcare Limited Balance Sheet (Rs in Hundreds)

 Be Swasth Healthcare Limited Profit & Loss Statement (Rs in Hundreds)

 Be Swasth Healthcare Limited Consolidated Cash Flow Statement (Rs in Hundreds)

Here is a summary of the Cash Flow Statement for the years 2024 and 2023:

Cash Flow from Operating Activities:

Operating activities reflect the cash generated or used by the company’s core business operations.

Net Profit before Tax increased significantly in 2024, reaching Rs. 7,085 (hundreds), compared to a loss of Rs. 3,130 in 2023. This shows a turnaround in the company's profitability.

Adjustments for Depreciation and Finance Costs are added back to the profit as they are non-cash expenses. Depreciation was lower in 2024 at Rs. 430 compared to Rs. 595 in 2023, suggesting either lesser capital expenditures or fully depreciated assets. Finance costs also dropped significantly.

The Operating Profit before Working Capital Changes rose dramatically to Rs. 7,521 in 2024, from a significant negative figure of Rs. -25,000 in 2023. This indicates much stronger operating performance in 2024.

However, when we factor in changes in working capital:

The Increase in Loans & Advances consumed Rs. 9,080 in cash in 2024, compared to Rs. 9,000 in 2023, suggesting a significant outflow toward this item, possibly indicating more lending or delayed payments from borrowers.

Sundry Debtors (accounts receivable) showed a positive impact, with a decrease in 2024 (Rs. 10,875), which contributed positively to cash flow, compared to a small decrease of Rs. 333 in 2023. This means the company collected more from its customers in 2024.

The Decrease in Current Liabilities (Rs. 7,283) in 2024 suggests that the company paid off a substantial portion of its short-term liabilities, resulting in a cash outflow, whereas it saw a significant increase in liabilities in 2023 (Rs. 11,524), which had contributed positively to cash in that year.

Other Current Assets slightly increased in both years, using up Rs. 499 and Rs. 604 in cash, respectively.

As a result, Cash Generated from Operations was negative in 2024, with a net outflow of Rs. 5,987, compared to a positive inflow of Rs. 2,253 in 2023. After accounting for taxes, the Net Cash from Operating Activities was negative in both years, though it slightly improved in 2024 at Rs. -250 compared to Rs. -247 in 2023. This suggests that the company's core business activities are still consuming cash, though the deficit is narrowing.

Cash Flow from Financing Activities:

Financing activities involve cash flows related to funding from external sources or repayments.

In 2024, the company incurred a Finance Cost of Rs. 5, compared to Rs. 35 in 2023. This suggests reduced borrowing or more favorable financing terms in 2024.

The Net Cash from Financing Activities was negative in both years, reflecting small outflows of Rs. 5 in 2024 and Rs. 35 in 2023. This indicates minimal financial activity, likely due to reduced borrowing or repayments.

Net Increase/(Decrease) in Cash and Cash Equivalents:

Despite improvements in profitability, the net cash position decreased in both years due to negative operating and financing cash flows.

The Net Decrease in Cash and Cash Equivalents was Rs. 255 in 2024, slightly less than the Rs. 282 decrease in 2023.

The Opening Balance of Cash and Cash Equivalents was Rs. 1,613 in 2024, declining from Rs. 1,896 in 2023.

The Closing Balance shows a deficit of Rs. 1,358 in 2024, compared to Rs. 1,613 in 2023, indicating a cash shortage by the end of the period.

Financial Ratios of Be Swasth Healthcare Limited

Here is a summary of the financial and operational metrics for Be Swasth Healthcare Limited for the year 2024 and 2023:

Current Ratio:

The current ratio measures a company’s ability to cover its short-term liabilities with its short-term assets. The values of 2.53 and 2.28 suggest that in both periods, the company is in a strong liquidity position. A ratio above 1 indicates that the company has more than enough current assets to meet its short-term obligations.

Return on Equity (ROE) Ratio:

ROE measures a company's profitability relative to shareholders' equity, showing how effectively it uses equity investments to generate profit. The ROE in the first period is 0.05 (or 5%), which indicates that the company generated a modest profit of 5 cents for every rupee of equity.

Trade Receivables Turnover Ratio:

This ratio measures how efficiently a company collects cash from its credit customers, calculated as the number of times trade receivables are collected during a period. In the first period, the ratio is 17.59, indicating that the company collected its trade receivables over 17 times during the year—a very high turnover, reflecting efficient collection processes and quick conversion of receivables into cash.

Net Capital Turnover Ratio:

The net capital turnover ratio measures how effectively the company is using its working capital to generate sales. The ratio is 0.32 in the first period and 0.28 in the second period, showing a slight decrease in how efficiently the company is using its working capital to generate revenue.

Net Profit Ratio:

The net profit ratio shows the percentage of revenue that translates into net profit, reflecting the company’s overall profitability. A 0.17 (17%) net profit ratio in the first period indicates a healthy profitability level, where 17% of sales are turned into profit. Return on Capital Employed (ROCE):

ROCE measures the profitability of a company in relation to the capital it employs (equity and debt), showing how efficiently capital is being used to generate profit. The first period’s ROCE of 0.07 (7%) indicates that the company is generating 7% returns on its capital, which is a modest but positive return.